{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:43:22Z","timestamp":1792687402137,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cllc.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:55:23Z","timestamp":1788620123000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-8243","authenticated-orcid":false,"given":"Jonathan W.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-6306","authenticated-orcid":false,"given":"Javier","family":"de Castro Carpe\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-4032","authenticated-orcid":false,"given":"Knut B.","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5512","authenticated-orcid":false,"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1204-1371","authenticated-orcid":false,"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-5159","authenticated-orcid":false,"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-0332","authenticated-orcid":false,"given":"Jonathan M.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-633X","authenticated-orcid":false,"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cllc.2026.09.001_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.cllc.2026.09.001_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.09.001_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cllc.2026.09.001_bib0004","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.cllc.2026.09.001_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.cllc.2026.09.001_bib0006","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.001_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cllc.2026.09.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.09.001_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2026.09.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/crj.70025","article-title":"Clinical management in NSCLC patients with EGFR mutation after osimertinib progression with unknown resistance mechanisms","volume":"18","author":"Liao","year":"2024","journal-title":"Clin Respir J"},{"key":"10.1016\/j.cllc.2026.09.001_bib0012","unstructured":"Hendriks LE, Cortiula F, Mariamidze E, Martins Branco D, Pentheroudakis G, Reck M. ESMO oncogene-addicted non-small cell lung cancer living guideline v1.2; 2025. Available at: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-oncogene-addicted-metastatic-non-small-cell-lung-cancer\/management-of-advanced-and-metastatic-disease."},{"issue":"4","key":"10.1016\/j.cllc.2026.09.001_bib0013","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.09.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02785","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.001_bib0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.001_bib0016","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cllc.2026.09.001_bib0017","unstructured":"US Food & Drug Administration (FDA). FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations; 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19"},{"key":"10.1016\/j.cllc.2026.09.001_sbref0018","series-title":"Summary of Product Characteristics","article-title":"Rybrevant 350 mg concentrate for solution for infusion","year":"2023"},{"key":"10.1016\/j.cllc.2026.09.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115693","article-title":"A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study","volume":"229","author":"Nagashima","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.09.001_bib0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)","volume":"6","author":"Yu","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2026.09.001_bib0021","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pst.1746","article-title":"Decision-making in early clinical drug development","volume":"15","author":"Frewer","year":"2016","journal-title":"Pharm Stat"},{"issue":"21","key":"10.1016\/j.cllc.2026.09.001_bib0022","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.001_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cllc.2026.09.001_bib0024","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cllc.2026.09.001_bib0025","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.cllc.2026.09.001_bib0026","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.09.001_bib0027","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1634\/theoncologist.2013-0168","article-title":"Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors","volume":"18","author":"Goldberg","year":"2013","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.cllc.2026.09.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.001_bib0029","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.cllc.2026.09.001_bib0030","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.09.001_bib0031","unstructured":"Planchard D, J\u00e4nne PA, Kobayashi K, et al. First-line osimertinib\u202f+\u202fchemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. Paper presented at: WCLC, Barcelona, Spain, 6\u20139 September 2025 [PL.02.06]. https:\/\/www.jto.org\/article\/S1556-0864(25)01065-2\/abstract."},{"issue":"12","key":"10.1016\/j.cllc.2026.09.001_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123096","article-title":"Distinct characteristics and clinical outcomes to predict the emergence of MET amplification in patients with non-small cell lung cancer who developed resistance after treatment with epidermal growth factor receptor tyrosine kinase inhibitors","volume":"13","author":"Ahn","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cllc.2026.09.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2021.05.002","article-title":"Co-occurring MET amplification predicts inferior clinical response to first-line erlotinib in advanced stage EGFR-mutated NSCLC patients","volume":"22","author":"Clement","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2026.09.001_bib0034","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1556-0864(25)00319-3","volume":"20","author":"Nadal","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.09.001_bib0035","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.09.001_bib0036","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jtho.2024.05.287","article-title":"PP01.50 SAFFRON: savolitinib\u202f+\u202fosimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib","volume":"19","author":"Piotrowska","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"S17","key":"10.1016\/j.cllc.2026.09.001_bib0037","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:34:54Z","timestamp":1792686894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1525730426001191"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}